| --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Investment Rating - The report maintains a "Buy" rating for the company, with a market price of RMB 44.48 and a sector rating of "Outperform" [2]. Core Insights - The company reported a revenue of RMB 99.4 billion for the first three quarters of 2024, representing a year-on-year increase of 18.9%, and a net profit attributable to shareholders of RMB 30.9 billion, up 17.1% year-on-year [4]. - In Q3 2024, the company's revenue was RMB 26.4 billion, a 10.1% increase year-on-year, while the net profit was RMB 6.2 billion, reflecting a 6.6% year-on-year growth [4]. - The company is actively adjusting its operational pace and focusing on deepening its market presence within the province, maintaining a strong competitive advantage [4]. Summary by Sections Financial Performance - For Q3 2024, the company achieved a revenue of RMB 26.4 billion and a net profit of RMB 6.2 billion, with respective year-on-year growth rates of 10.1% and 6.6% [6]. - The company's gross margin for Q3 2024 was 75.6%, down 5.1 percentage points year-on-year, primarily due to increased promotional efforts [6]. - The company’s total revenue for the first three quarters of 2024 reached RMB 99.4 billion, with a net profit of RMB 30.9 billion, marking an 18.9% and 17.1% increase year-on-year, respectively [4][6]. Market Strategy - The company is focusing on its core products, with the premium product line (priced above RMB 300) generating RMB 18.1 billion in revenue, accounting for 68.8% of total revenue [4]. - The company has expanded its distributor network to 1,193, with 588 distributors in the province and 605 in other regions, indicating a strategic focus on both local and external markets [4]. Valuation and Forecast - The report adjusts the revenue growth forecast for 2024 to 17.2%, with net profit growth projected at 16.1% [5]. - The expected earnings per share (EPS) for 2024 is RMB 2.90, with corresponding price-to-earnings (P/E) ratios of 15.3X for 2024, 13.5X for 2025, and 11.9X for 2026 [5].

Investment Rating - The investment rating for the company is "Buy" with a previous rating of "Buy" as well [1] Core Views - The report highlights that Shanxi Fenjiu has shown steady growth in its third-quarter performance for 2024, with revenue reaching RMB 31.36 billion, a year-on-year increase of 17.3%, and net profit attributable to shareholders of RMB 11.35 billion, up 20.3% year-on-year [3][5] - The company has demonstrated strong cash flow performance, with a notable increase in sales cash receipts by 30.8% year-on-year in the third quarter [3] - The report anticipates revenue growth rates of 16.5%, 11.6%, and 11.1% for 2024, 2025, and 2026 respectively, with net profit growth rates of 19.7%, 13.7%, and 12.3% for the same years [4][6] Summary by Sections Company Performance - In Q3 2024, the company achieved revenue of RMB 8.61 billion, a year-on-year increase of 11.4%, and a net profit of RMB 2.94 billion, up 10.4% year-on-year [5] - The gross profit margin for Q3 2024 was 74.3%, slightly down by 0.7 percentage points compared to the previous year [5] - The company’s contract liabilities decreased to RMB 5.48 billion, reflecting a reduction of RMB 250 million from the previous quarter [3] Revenue Breakdown - The revenue from mid-to-high-end liquor in Q3 2024 was RMB 6.19 billion, a year-on-year increase of 6.7%, showing an acceleration compared to Q2 2024 [3] - Revenue from other liquor categories grew significantly by 25.6% year-on-year, accounting for 28.0% of total revenue [3] Regional Performance - Revenue from the domestic market reached RMB 3.51 billion, a year-on-year increase of 12.1%, while revenue from outside the province was RMB 5.09 billion, up 10.9% year-on-year [3] Financial Projections - The report projects earnings per share (EPS) of RMB 10.24, 11.65, and 13.08 for 2024, 2025, and 2026 respectively, with corresponding price-to-earnings (P/E) ratios of 20.4X, 17.9X, and 16.0X [4][6] - The company’s EBITDA is expected to grow from RMB 17.19 billion in 2024 to RMB 21.21 billion by 2026 [4][6]

| --- | --- | --- | --- | --- | |-----------------------------------------|------------------------------------------------------|------------------------|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 证券研究报告 \n11 月金股组合 股票代码 | —— | 晨会聚焦 \n股票名称 | | 2024 年 11 月 4 日 \n中银晨会聚焦 -20241104 | | 600383.SH | | 金地集团 | | | | 1519.HK | | 极兔速递 | -W | | | | | | | ■ 重点关注 | | 600309. ...

Investment Rating - The report maintains a "Buy" rating for the company, Wuliangye [1][2]. Core Views - The company has adjusted its operational pace, which has positively impacted shareholder confidence. The announcement of a shareholder return plan for 2024-2026 is expected to enhance investor sentiment [1]. - Despite a short-term pressure on the external consumption environment, the long-term development of the leading brand is viewed positively [1]. Summary by Sections Financial Performance - For the first three quarters of 2024, the company reported revenue of RMB 67.92 billion, a year-on-year increase of 8.6%, and a net profit attributable to shareholders of RMB 24.93 billion, up 9.2%. In Q3 2024, revenue and net profit were RMB 17.27 billion and RMB 5.87 billion, respectively, reflecting year-on-year growth of 1.4% and 1.3% [1][5]. - The company's gross margin improved by 2.8 percentage points year-on-year to 76.2% in Q3 2024, attributed to the execution of new pricing policies by distributors [1][5]. Shareholder Returns - The company announced a shareholder return plan for 2024-2026, committing to a cash dividend of no less than 70% of the annual net profit, with a minimum of RMB 20 billion each year. This represents a significant increase in the dividend payout ratio compared to previous years [1][4]. Revenue and Profit Forecast - The report has adjusted its revenue forecasts for 2024-2026, expecting year-on-year growth rates of 8.1%, 5.7%, and 8.0%, respectively. Net profit is projected to grow by 8.0%, 5.6%, and 8.3% over the same period [1][4]. - The earnings per share (EPS) estimates for 2024, 2025, and 2026 are RMB 8.40, RMB 8.87, and RMB 9.61, respectively, with corresponding price-to-earnings (PE) ratios of 17.5X, 16.5X, and 15.3X [1][4]. Market Position - The company is recognized as a leading brand in the liquor industry, and its proactive adjustments in product distribution and marketing strategies are expected to support its market position in the long term [1][2].

Investment Rating - The report rates the chemical industry as "Outperform" [1] Core Views - The report suggests focusing on leading companies in the refrigerant and vitamin sectors due to their high market sentiment. It also highlights the importance of macroeconomic improvements and the potential of undervalued leading companies in the industry [1][5] - The report emphasizes the need for high-quality development and shareholder returns, particularly in large energy state-owned enterprises and related oil service companies [1][5] - It identifies several catalysts, including the third phase of major funds and downstream expansions, which could benefit semiconductor and OLED electronic materials companies [1][5] Summary by Sections Industry Dynamics - During the week of October 28 to November 3, 2024, among 101 tracked chemical products, 28 saw price increases, 43 saw decreases, and 30 remained stable. The most significant price increases were observed in sulfur, liquid chlorine, and anhydrous hydrofluoric acid, while the largest decreases were in epoxy chloropropane, WTI crude oil, and vitamin A [1][23] - International oil prices initially fell before rising, with WTI crude oil futures closing at $69.49 per barrel, a weekly decline of 1.81%, and Brent crude at $72.94 per barrel, down 2.95% [1][23] - The report notes that U.S. gasoline demand remains strong, with total refined oil demand averaging 20.94 million barrels per day, up 2.7% year-on-year [1][23] Investment Recommendations - As of November 3, 2024, the SW basic chemical sector's price-to-earnings ratio (TTM) is 21.42, at the 56.74% historical percentile, while the price-to-book ratio is 1.79, at the 10.28% historical percentile [1][5] - The report recommends focusing on high-sentiment sectors such as refrigerants and vitamins, as well as undervalued leading companies in the light hydrocracking sub-industry [1][5] - Long-term investment themes include the sustained high sentiment in the oil and gas extraction sector, the potential recovery of the semiconductor industry, and the ongoing demand in sub-industries like fluorochemicals and animal nutrition [1][5] Key Stocks - Recommended stocks include China Petroleum, China National Offshore Oil Corporation, China Petrochemical Corporation, and several technology and chemical companies such as Anji Technology and Wanhua Chemical [1][5]

Group 1 - The report indicates that domestic demand is showing positive signals, with the A-share market experiencing high-level platform fluctuations and a lack of clear market themes. The October PMI data has ended five consecutive months of contraction, returning to the expansion zone, indicating a recovery in production and demand [3][9] - The real estate transaction data for October shows signs of marginal recovery, with new housing transaction volume increasing by 0.9% year-on-year, marking the first growth since June of last year. The overall transaction volume for new and second-hand homes has also seen a year-on-year increase of 3.9% [3][9] - The upcoming U.S. elections and important meetings in China are expected to significantly influence asset prices and market direction. Current market expectations lean towards a high probability of Trump's victory, which could impact China's fiscal policy and economic growth strategies [3][10] Group 2 - The report highlights the trend of the AI industry evolving towards terminal devices and applications, with A-share AI concepts likely to benefit. The development of the technology industry typically follows a cycle from hardware infrastructure to terminal devices and software applications, with current high demand in computing infrastructure [3][24] - The launch of the AI agent AutoGLM by Zhizhu AI, which can perform various tasks on mobile and web platforms, is noted as a significant advancement in AI applications. This product is expected to enhance the user experience and drive further adoption of AI technologies [3][22][23] - The report suggests focusing on sectors such as consumer electronics and various AI applications, including AI in driving, finance, education, and gaming, which are anticipated to see early implementation and growth [3][24]

Investment Rating - The report rates the pharmaceutical and biotechnology industry as "Outperform" [1] Core Insights - The U.S. plays a crucial role in the global pharmaceutical industry, serving as a significant revenue source for both domestic and European pharmaceutical companies. The U.S. market is particularly friendly to innovative drug pricing, which influences global pricing strategies [8][9] - The U.S. healthcare system's payment structure offers valuable insights for other countries, with diverse payment systems balancing cost control and provider incentives. The changes in the U.S. payment system may create new market opportunities for Chinese pharmaceutical companies [9][10] Summary by Sections 1. Payment Total and Distribution - The U.S. has the highest per capita healthcare spending among OECD countries, with 2019 figures showing $11,072 per person, significantly above the OECD average of $4,224 [11] - Healthcare providers and pharmaceutical companies benefit from high U.S. healthcare spending, with hospital services accounting for 33% of total healthcare expenditure in 2018 [13][14] - In 2021, U.S. per capita spending on outpatient and inpatient services reached $7,500, approximately 2.5 times higher than comparable countries [16] 2. Payment Sources - The U.S. healthcare payment system is diverse, including public insurance, private insurance, and out-of-pocket payments. Public insurance primarily covers the elderly and low-income individuals [24][26] - In 2022, 68.7% of the U.S. population was covered by private insurance, with 54.8% through employer-sponsored plans [26][28] - Public insurance programs like Medicare and Medicaid play a significant role, covering 18.5% and 21.2% of the population, respectively [26][28] 3. Payment Standards - The U.S. has a varied payment standard for healthcare services, with different standards applied by various payers. Medicare and Medicaid utilize cost control measures, while private insurance offers more flexibility [30][31] - The U.S. pharmaceutical pricing system is influenced by Pharmacy Benefit Managers (PBMs), which negotiate prices between drug manufacturers and insurers, contributing to high drug costs [21][22] - The Inflation Reduction Act (IRA) allows the government to negotiate prices for certain drugs under Medicare, marking a shift in the U.S. approach to drug pricing [46]

Investment Rating - The report maintains an "Outperform" rating for the power equipment and new energy industry [1]. Core Views - The report highlights strong sales in the new energy vehicle sector, with notable growth in companies like BYD and Seres, indicating a robust demand outlook for the industry [1][14]. - In the photovoltaic sector, energy consumption control policies are expected to be implemented, potentially reversing supply-demand dynamics in the silicon material segment, while component price increases are anticipated to enhance profitability for leading manufacturers [1]. - The wind power sector is expected to see steady progress in domestic offshore and onshore bidding and construction, with positive demand forecasts for the coming year [1]. - The report suggests prioritizing investments in sectors likely to see profit improvements, particularly in complete machines and casting segments benefiting from offshore wind and international expansion [1]. - The hydrogen energy sector is also highlighted, with ongoing policy support for industrial development, recommending attention to companies with cost and technological advantages in electrolyzer production [1]. Summary by Sections Industry Performance - The power equipment and new energy sector experienced a decline of 2.82% this week, with specific segments like power generation equipment increasing by 2.47% and nuclear power rising by 0.6% [1][7]. - The report notes significant sales figures for new energy vehicles, with BYD selling 502,700 units in October, a year-on-year increase of 66.2% [1][14]. Key Industry Information - The report mentions that major companies are actively engaging in new technology developments, such as the solid-state lithium battery launch by Changan and Tai Lan New Energy [1][14]. - It also highlights significant project wins, such as Oriental Cable winning a contract for a 500kV submarine cable for an offshore wind farm, valued at approximately 800 million yuan [1][14]. Company Updates - Companies like SANY Heavy Energy have secured substantial wind turbine sales contracts in India, totaling 1,624 MW [1]. - The report notes that XJ Electric and related subsidiaries are expected to win bids for significant procurement projects from the State Grid Corporation, amounting to approximately 1.338 billion yuan [1][19].

Economic Indicators - The manufacturing PMI for October is reported at 50.1%, an increase of 0.3 percentage points from September, marking a return to the expansion zone for the first time since May 2024[1][2][20]. - New orders index stands at 50.0%, up 0.1 percentage points from September, while the production index is at 52.0%, reflecting a growth of 0.8 percentage points[2][20]. Monetary Policy - The central bank conducted a 6-month reverse repurchase operation of 500 billion yuan in October, with a net long-term fund injection exceeding 600 billion yuan for the month, indicating a supportive monetary policy stance[1][22]. - The net purchase of government bonds amounted to 200 billion yuan in October, further supporting liquidity in the market[22]. Asset Performance - The CSI 300 index fell by 1.68% this week, while the CSI 500 index saw a slight increase of 0.38%[1][33]. - The yield on 10-year government bonds decreased by 1 basis point to 2.14%, with active futures rising by 0.29%[1][13]. Investment Strategy - Recommended asset allocation order is: equities > commodities > bonds > cash, reflecting a positive outlook on equities due to the implementation of incremental policies[2][3]. - Risks include slow global inflation decline, rapid economic downturns in Europe and the US, and complex international situations[2].